TransMedics: Numb Reaction To Extraordinary Fundamentals

Impact · against what's priced in

TransMedics demonstrates strong fundamental momentum with significant margin expansion and a clear path to diversified growth across organ programs. The combination of a Q4 beat and positive 2026 guidance suggests the company is scaling efficiently.

TMDX+0.70

No priced-in read yet

In context

The company reported 32% Y/Y revenue growth and a 610 bps expansion in operating margins, while providing 20-25% revenue growth guidance for 2026.

Read from the article alone

• healthcare▲13%
• guidance▲9%
• earnings▲3%
• TMDX
• growth
• medical devices
• profitability